Novel synthetic (poly)glycerolphosphate-based antistaphylococcal conjugate vaccine

Infection and Immunity

Volumn 81, Issue 7, 2013, Pages 2554-2561

  Chen, Quanyi ^a   Dintaman, Jay ^a   Lees, Andrew ^b   Sen, Goutam ^a,h   Schwartz, David ^c   Shirtliff, Mark E ^d,e   Park, Saeyoung ^f   Lee, Jean C ^f   Mond, James J ^g   Snapper, Clifford M ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Fina Biosolutions LLC   (United States)

^c Solulink Inc   (United States)

^d UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BioConsultingSolutions   (United States)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(POLY)GLYCEROLPHOSPHATE; GLYCEROL PHOSPHORAMIDITE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; LIPOTEICHOIC ACID; PHOSPHORAMIDOUS ACID DERIVATIVE; STAPHYLOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; DRUG SYNTHESIS; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOMYELITIS; PERITONEUM CELL; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYNTHESIS; T CELL DEPLETION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; BACTEREMIA; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GLYCEROPHOSPHATES; IMMUNE SERA; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; OLIGODEOXYRIBONUCLEOTIDES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; TETANUS TOXOID; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 84879430573     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00271-13     Document Type: Article

References (67)

1. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. 2007. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 28:1047-1053
2. McCaig LF, McDonald LC, Mandal S, Jernigan DB. 2006. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg. Infect. Dis. 12:1715-1723
3. Lew DP, Waldvogel FA. 2004. Osteomyelitis. Lancet 364:369 -379
4. Schultz KD, Fan LL, Pinsky J, Ochoa L, Smith EO, Kaplan SL, Brandt ML. 2004. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics 113:1735-1740
5. Fowler VG, Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021
6. Rupp ME, Archer GL. 1994. Coagulase-negative staphylococci: pathogens associated with medical progress. Clin. Infect. Dis. 19:231-243quiz; 19:44-45
7. Götz F. 2002. Staphylococcus and biofilms. Mol. Microbiol. 43:1367- 1378
8. von Eiff C, Peters G, Heilmann C. 2002. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect. Dis. 2:677- 685
9. Raad I, Hanna H, Maki D. 2007. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect. Dis. 7:645- 657
10. Knox KW, Wicken AJ. 1973. Immunological properties of teichoic acids. Bacteriol. Rev. 37:215-257
11. Xia G, Kohler T, Peschel A. 2010. The wall teichoic acid and lipoteichoic acid polymers of Staphylococcus aureus. Int. J. Med. Microbiol. 300:148- 154
12. Frederick TG, Chorpenning FW. 1974. Characterization of antibodies specific for polyglycerophosphate. J. Immunol. 113:489-495
13. Jackson DE, Wicken AJ, Jackson GD. 1981. Immune responses to lipoteichoic acid: comparison of antibody responses in rabbits and mice. Part II. Int. Arch. Allergy Appl. Immunol. 65:203-211
14. Theilacker C, Kaczynski Z, Kropec A, Fabretti F, Sange T, Holst O, Huebner J. 2006. Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid. Infect. Immun. 74:5703- 5712
15. Yokoyama Y, Harabuchi Y. 2002. Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int. J. Pediatr. Otorhinolaryngol. 63:235-241
16. Fischer W, Mannsfeld T, Hagen G. 1990. On the basic structure of poly(glycerophosphate) lipoteichoic acids. Biochem. Cell Biol. 68:33- 43
17. Doyle RJ, Sonnenfeld EM, Cost K, Thaniyavarn S. 1982. Antipoly(glycerolphosphate) in human sera. J. Clin. Microbiol. 15:1169 -1171
18. Theilacker C, Kropec A, Hammer F, Sava I, Wobser D, Sakinc T, Codee JD, Hogendorf WF, van der Marel GA, Huebner J. 2012. Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J. Infect. Dis. 205:1076 -1085
19. Fischer W. 1990. Bacterial phosphoglycolipids and lipoteichoic acids, p 123-233. In KatesM(ed), Handbook of lipid research. Plenum Press, New York, NY
20. Zahringer U, Lindner B, Inamura S, Heine H, Alexander C. 2008. TLR2 -promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213:205-224
21. Morath S, Stadelmaier A, Geyer A, Schmidt RR, Hartung T. 2002. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J. Exp. Med. 195:1635-1640
22. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274:17406 -17409
23. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. 2005. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 26:166 -174
24. Schaffer AC, Lee JC. 2009. Staphylococcal vaccines and immunotherapies. Infect. Dis. Clin. North Am. 23:153-171
25. Mond JJ, Lees A, Snapper CM. 1995. T cell-independent antigens type 2. Annu. Rev. Immunol. 13:655- 692
26. Avery OT, Goebel WF. 1931. Chemo-immunological studies on conjugated carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J. Exp. Med. 54:437- 447
27. Ahmad H, Chapnick EK. 1999. Conjugated polysaccharide vaccines. Infect. Dis. Clin. North Am. 13:113-133, vii
28. Beuvery EC, van Rossum F, Nagel J. 1982. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect. Immun. 37:15-222
29. Schneerson R, Barrera O, Sutton A, Robbins JB. 1980. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361-376
30. Frisch J, Houchins JP, Grahek M, Schoephoerster J, Hagen J, Sweet J, Mendoza L, Schwartz D, Kalyuzhny AE. 2011. Novel multicolor immunofluorescence technique using primary antibodies raised in the same host species. Methods Mol. Biol. 717:233-244
31. Fredriksson S, Dixon W, Ji H, Koong AC, Mindrinos M, Davis RW. 2007. Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat. Methods 4:327-329
32. Khan AQ, Lees A, Snapper CM. 2004. Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+T cell help. J. Immunol. 172:532-539
33. Prabhakara R, Harro JM, Leid JG, Harris M, Shirtliff ME. 2011. Murine immune response to a chronic Staphylococcus aureus biofilm infection. Infect. Immun. 79:1789 -1796
34. Cerca N, Jefferson KK, Maira-Litran T, Pier DB, Kelly-Quintos C, Goldmann DA, Azeredo J, Pier GB. 2007. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1- 6)-glucosamine. Infect. Immun. 75:3406 -3413
35. Voyich JM, Braughton KR, Sturdevant DE, Whitney AR, Said-Salim B, Porcella SF, Long RD, Dorward DW, Gardner DJ, Kreiswirth BN, Musser JM, DeLeo FR. 2005. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J. Immunol. 175:3907-3919
36. Li D, Gromov K, Soballe K, Puzas JE, O'Keefe RJ, Awad H, Drissi H, Schwarz EM. 2008. Quantitative mouse model of implant-associated osteomyelitis and the kinetics of microbial growth, osteolysis, and humoral immunity. J. Orthop. Res. 26:96 -105
37. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME. 2006. Identification of Staphylococcus aureus proteins recognized by the anti-body-mediated immune response to a biofilm infection. Infect. Immun. 74:3415-3426
38. Sen G, Flora M, Chattopadhyay G, Klinman DM, Lees A, Mond JJ, Snapper CM. 2004. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity. Cell. Immunol. 232:64 -74
39. Chen Q, Cannons JL, Paton JC, Akiba H, Schwartzberg PL, Snapper CM. 2008. A novel ICOS-independent, but CD28- and SAP-dependent, pathway of T cell-dependent, polysaccharide-specific humoral immunity in response to intact Streptococcus pneumoniae versus pneumococcal conjugate vaccine. J. Immunol. 181:8258-8266
40. Burton RL, Nahm MH. 2012. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin. Vaccine Immunol. 19:835- 841
41. Thakker M, Park JS, Carey V, Lee JC. 1998. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect. 0Immun. 66:5183- 5189
42. Snapper CM. 2012. Mechanisms underlying in vivo polysaccharidespecific immunoglobulin responses to intact extracellular bacteria. Ann. N. Y. Acad. Sci. 1253:92-101
43. Seale A, Finn A. 2011. What is the best way to use conjugate vaccines? Curr. Opin. Infect. Dis. 24:219 -224
44. Caldwell J, Lehner T. 1982. Immunisation of rhesus monkeys with Streptococcus mutans, Lactobacillus acidophilus and lipoteichoic acid for protection against dental caries. J. Med. Microbiol. 15:339 -350
45. Morath S, Geyer A, Hartung T. 2001. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med. 193:393-397
46. Hogendorf WF, Bos LJ, Overkleeft HS, Codee JD, Marel GA. 2010. Synthesis of an alpha-kojibiosyl substituted glycerol teichoic acid hexamer. Bioorg. Med. Chem. 18:3668 -3678
47. Hogendorf WF, Kropec A, Filippov DV, Overkleeft HS, Huebner J, van der Marel GA, Codee JD. 2012. Light fluorous synthesis of glucosylated glycerol teichoic acids. Carbohydr. Res. 356:142-151
48. Guttormsen HK, Sharpe AH, Chandraker AK, Brigtsen AK, Sayegh MH, Kasper DL. 1999. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect. Immun. 67:6375- 6384
49. Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lindberg FP. 2000. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol. 164:3713-3722
50. Graveline R, Segura M, Radzioch D, Gottschalk M. 2007. TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. Int. Immunol. 19:375-389
51. Colino J, Snapper CM. 2003. Two distinct mechanisms for induction of dendritic cell apoptosis in response to intact Streptococcus pneumoniae. J. Immunol. 171:2354-6552
52. Risley AL, Loughman A, Cywes-Bentley C, Foster TJ, Lee JC. 2007. Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets. J. Infect. Dis. 196:919- 927
53. Miller LG, Kaplan SL. 2009. Staphylococcus aureus: a community pathogen. Infect. Dis. Clin. North Am. 23:35-52
54. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346:491- 496
55. Proctor RA. 2012. Is there a future for a Staphylococcus aureus vaccine? Vaccine 30:2921-2927
56. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F, Morris A, Kapik B, Roberson D, Kesler K, Patti J, Hetherington S. 2007. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 151:260 -265, 5e1
57. Patti JM. 2004. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22(Suppl 1):S39 -S43
58. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205:287-294
59. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alphahemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 202:1050 -1058
60. LeClaire RD, Hunt RE, Bavari S. 2002. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect. Immun. 70:2278 -2281
61. Hu DL, Omoe K, Sasaki S, Sashinami H, Sakuraba H, Yokomizo Y, Shinagawa K, Nakane A. 2003. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J. Infect. Dis. 188:743-752
62. Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG, Jr. 2009. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J. Clin. Microbiol. 47:3952-3957
63. Hermos CR, Yoong P, Pier GB. 2010. High levels of antibody to Panton-Valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin. Infect. Dis. 51: 1138-1146
64. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, Fujikado N, Tanahashi Y, Akitsu A, Kotaki H, Sudo K, Nakae S, Sasakawa C, Iwakura Y. 2009. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30:108 -119
65. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, Bayer AS, Filler SG, Lipke P, Otoo H, Edwards JE, Jr. 2008. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect. Immun. 76:4574- 4580
66. Joshi A, Pancari G, Cope L, Bowman EP, Cua D, Proctor RA, McNeely T. 2012. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum. Vaccin. Immunother. 8:336 -346
67. Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y, Nakane A. 2010. Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect. Immun. 78:4234-4242.